<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499616</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL0531</org_study_id>
    <secondary_id>COG-ANBL0531</secondary_id>
    <secondary_id>NCI-2009-00400</secondary_id>
    <nct_id>NCT00499616</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma</brief_title>
  <official_title>Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and
      doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either
      by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma
      cells become more like normal cells, and grow and spread more slowly. Giving combination
      chemotherapy before surgery may make the tumor smaller and make it more likely that the tumor
      can be surgically removed. It is not yet known what is the minimal amount of chemotherapy
      needed to achieve sufficient tumor shrinkage to control intermediate risk neuroblastoma and
      prevent tumor recurrence or metastases.

      PURPOSE: This phase III trial is designed to reduce therapy for patients with favorable
      biology intermediate risk neuroblastoma by decreasing the number of chemotherapy cycles
      administered and by allowing for up to 50% residual tumor volume for patients with localized
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Reduce therapy for patients with intermediate-risk neuroblastoma while maintaining a
           3-year overall survival (OS) rate of ≥ 95% by using a response-based duration of therapy
           algorithm.

        -  Maintain an overall 3-year OS rate of ≥ 90% for patients within each group.

        -  Utilize loss of heterozygosity, prospectively, at 1p36 and 11q23 to refine
           risk-stratification and treatment assignment, allowing patients whose tumors lack these
           chromosomal abnormalities to receive a reduction in therapy, and compare the outcome
           with patients treated on COG-A3961.

        -  Reduce intensity of therapy for patients 365 to &lt; 547 days (12-18 months) of age with
           stage 4 neuroblastoma and favorable biological features and maintain a 3-year event-free
           survival (EFS) rate consistent with that for patients &lt; 1 year of age with stage 4
           neuroblastoma treated on COG-A3961.

        -  Reduce intensity of therapy for patients 365 to &lt; 547 days (12-18 months) of age with
           stage 3 MYCN-nonamplified but unfavorable histology neuroblastoma and maintain a 3-year
           EFS rate consistent with that for patients &lt; 1 year of age with stage 3,
           MYCN-nonamplified, unfavorable histology neuroblastoma treated on COG-A3961.

        -  Reduce surgical morbidity for patients with stage 4S neuroblastoma by allowing for
           biopsy only, rather than complete surgical resection, of the primary tumor.

        -  Systematically study the outcome of patients with stage 4S neuroblastoma who are unable
           to undergo biopsy for biology-based risk assignment.

        -  Determine if the extent of surgical resection correlates with the maintenance of local
           control, EFS and/or OS rates, and surgical complication rate.

      Secondary

        -  Determine the results of a standard retrieval approach for patients with residual
           disease after 8 courses of initial therapy.

        -  Determine the results of a standard retrieval approach for patients with progressive,
           nonmetastatic disease.

        -  Identify additional biological surrogate markers for disease relapse and/or metastatic
           progression.

        -  Describe the neurologic outcome of patients with paraspinal neuroblastoma primary
           tumors.

        -  Correlate surgical biopsy technique with adequacy of tissue acquisition for biologic
           studies and with complications associated with the biopsy procedure.

        -  Prospectively validate the prognostic ability of the International Neuroblastoma Risk
           Group image-defined risk factor system, and compare the institutional assessment of
           image-defined risk factors with that of central review.

      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 3 treatment groups by
      risk-stratification based on age, stage (INSS stage 2, 3, 4, or 4S), MYCN status (amplified
      vs not amplified), histopathologic classification, tumor DNA index, and allelic status at
      chromosome bands 11q23 and 1p36.

        -  Initial chemotherapy: Courses of initial chemotherapy are administered every 21 days
           according to group assignment as outlined below:

             -  Course 1: Patients receive carboplatin IV over 1 hour on day 1 and etoposide IV
                over 1 hour on days 1-3.

             -  Course 2: Patients receive carboplatin IV over 1 hour, cyclophosphamide IV over 1
                hour, and doxorubicin hydrochloride IV over 15 minutes on day 1.

             -  Course 3: Patients receive cyclophosphamide IV over 1 hour on day 1 and etoposide
                IV over 1 hour on days 1-3.

             -  Course 4: Patients receive carboplatin IV over 1 hour and doxorubicin hydrochloride
                IV over 15 minutes on day 1 and etoposide IV over 1 hour on days 1-3.

             -  Course 5: Patients receive cyclophosphamide IV over 1 hour on day 1 and etoposide
                IV over 1 hour on days 1-3.

             -  Course 6: Patients receive carboplatin IV over 1 hour, cyclophosphamide IV over 1
                hour, and doxorubicin hydrochloride IV over 15 minutes on day 1.

             -  Course 7: Patients receive carboplatin IV over 1 hour on day 1 and etoposide IV
                over 1 hour on days 1-3.

             -  Course 8: Patients receive cyclophosphamide IV over 1 hour and doxorubicin
                hydrochloride IV over 15 minutes on day 1.

                  -  Group 2: Patients receive 2 courses of initial chemotherapy. Patients with a
                     partial response (PR) (50-90% reduction in volume) to chemotherapy proceed to
                     observation. Patients without a PR receive 2-6 additional courses of
                     chemotherapy (beginning with course 3). Patients who do not achieve a PR after
                     additional chemotherapy proceed to retrieval chemotherapy.

                  -  Group 3: Patients receive 4 courses of initial chemotherapy. Patients with a
                     PR after chemotherapy proceed to observation. Patients without a PR receive
                     2-4 additional courses of chemotherapy (beginning with course 5). Patients who
                     do not achieve a PR after additional chemotherapy proceed to retrieval
                     chemotherapy.

                  -  Group 4: Patients receive 8 courses of initial chemotherapy. Patients under 12
                     months of age with stage 3, 4, or 4S disease who achieve a very good PR (VGPR)
                     (&gt; 90% reduction in the volume of the primary tumor and resolution of
                     metastatic disease, with the exception of liver and skin metastases) to
                     chemotherapy proceed to observation. Patients 12-18 months of age with stage 3
                     or 4 disease [age 365 to &lt; 547 days at diagnosis, INSS stage 3, MYCN-NA,
                     unfavorable histology, any ploidy and patients age 365 to &lt; 547 days at
                     diagnosis, INSS stage 4, MYCN-NA, favorable histology, DI &gt; 1] who achieve a
                     VGPR proceed to isotretinoin therapy. Patients who do not achieve a VGPR after
                     8 courses of initial chemotherapy +/- surgery will proceed to retrieval
                     chemotherapy with cyclophosphamide/topotecan for 2-6 courses until a VGPR can
                     be achieved with a combination of chemotherapy and surgery.

        -  Retrieval chemotherapy*: Patients receive cyclophosphamide IV over 30 minutes and
           topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6
           courses.

             -  Groups 2 and 3: Patients with a PR after 2-6 courses of retrieval chemotherapy
                proceed to observation. Patients without a PR after 2-6 courses of retrieval
                chemotherapy are removed from protocol therapy.

             -  Group 4: Patients under 12 months of age with stage 4 disease with a VGPR after
                retrieval chemotherapy proceed to observation. Patients 12-18 months of age with
                stage 3 or 4 disease who achieve a VGPR after retrieval chemotherapy proceed to
                isotretinoin therapy. Patients who do not achieve a VGPR after retrieval
                chemotherapy are removed from protocol therapy.

      Group 4 patients who develop progressive, non-metastatic disease within 3 years of study
      enrollment will also receive retrieval chemotherapy with cyclophosphamide and topotecan.

      NOTE: *Patients who have previously received cyclophosphamide and topotecan to achieve first
      PR/VGPR are not eligible for this Retrieval Therapy.

        -  Surgery: With the exception of patients with INSS 4S disease, patients undergo surgery
           to remove as much of the primary tumor and involved lymph nodes as can safely be
           accomplished. Reassessment for definitive surgery (for patients who undergo biopsy only
           or partial resection at diagnosis) is made at the completion of scheduled chemotherapy
           (after course 2 for group 2, after course 4 for group 3, and after course 8 for group
           4).

        -  Isotretinoin therapy: Beginning 3-4 weeks after completion of chemotherapy or 2 weeks
           post-operatively (for patients who undergo surgical resection), patients receive oral
           isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for 6 courses in
           the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed up periodically for up to 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) Rates</measure>
    <time_frame>3 years</time_frame>
    <description>OS time is calculated from date of enrollment until death, or until last contact if the patient is alive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Definitive Determination of the Prognostic Ability of 1p and 11q</measure>
    <time_frame>At baseline</time_frame>
    <description>Addressed by a descriptive comparison of the EFS and OS rates for patients with 1p loss vs without 1p loss, and for those with unbalanced 11q vs normal 11q.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Between Reduce Intensity of Therapy for Patients With Stage 4 Neuroblastoma and Favorable Biological Features and Patients &lt; 1 Year of Age With Stage 4 Neuroblastoma Treated on COG-A3961</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients &lt; 1 yrs of age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison Between Reduce Intensity of Therapy for Patients With Unfavorable Histology Neuroblastoma and Patients Unfavorable Histology Neuroblastoma Treated on COG-A3961</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients &lt; 1 yrs of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduced Surgical Morbidity for Patients With Stage 4S Neuroblastoma</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Descriptive analyses of the proportion of stage 4S infants that experience a surgical or post-operative event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of Patients With Stage 4S Neuroblastoma Who Are Unable to Undergo Biopsy for Biology-based Risk Assignment</measure>
    <time_frame>From baseline to up to 10 years</time_frame>
    <description>Kaplan-Meier curves and lifetables of Event Free Survival (EFS) and Overall Survival (OS) rates will be generated to describe the outcome of the stage 4S infants unable to undergo biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Event Free Survival (EFS)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>To test the predictive ability of the extent of surgical resection for EFS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Overall Survival (OS) Rates</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>To test the predictive ability of the extent of surgical resection for OS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Surgical Complication Rate</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>To test for the association of the extent of surgical resection (CR vs &lt;CR) with surgical complications rate (complications of any kind vs no complications at all), a chi-square test will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Second-event-free Survival (E2FS) of Intermediate Risk Patients</measure>
    <time_frame>From the time of the first progressive, non-metastatic event until the subsequent occurrence of relapse, progressive disease, secondary malignancy, or death</time_frame>
    <description>Kaplan-Meier curves and life tables of E2FS and OS (from the time of first event) will be generated to describe the outcome for patients who have a first progressive, non-metastatic event during Observation and then receive protocol retrieval therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time</measure>
    <time_frame>From the time of the first progressive, non-metastatic event</time_frame>
    <description>Kaplan-Meier curves and life tables of E2FS and OS (from the time of first event) will be generated to describe the outcome for patients who have a first progressive, non-metastatic event during Observation and then receive protocol retrieval therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Surrogate Markers</measure>
    <time_frame>At baseline and surgery</time_frame>
    <description>Multivariable analyses will be performed to identify variables of prognostic interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Neurologic Symptoms Overall and Type of Symptom</measure>
    <time_frame>On treatment and post-treatment</time_frame>
    <description>Descriptive analysis will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Surgical Biopsy Technique With Adequacy of Tissue Acquisition for Biologic Studies, and With Complications Associated With the Biopsy Procedure</measure>
    <time_frame>During and after surgery</time_frame>
    <description>A chi-square test will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic Ability of the INRG Image-defined Risk Factor (IDRF) System</measure>
    <time_frame>At baseline, during and after completion of study treatment</time_frame>
    <description>A Kaplan - Meier curves of presence vs absence of one or more IDRFs will be generated, and a log rank test performed to compare them, for EFS and OS. The IDRF data will be used to determine the International Neuroblastoma Risk Group Stage (INRGSS) and Kaplan-Meier curves by INRGSS will be generated. To compare the institutional assessment of IDRFs (presence vs absence) with the central review assessment of IDRFs, a chi-square test will be performed. ROC curves will be generated, and the sensitivity and specificity of the institutional assessment will be calculated</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">464</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-intermediate risk enrolled on intermediate risk trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>NSC #241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>NSC #26271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>NSC #123127</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>VePesid</other_name>
    <other_name>VP-16</other_name>
    <other_name>NSC #141540</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>SKF-104864</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>NSC #60969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>13-cis-retinoic acid</other_name>
    <other_name>RO-43</other_name>
    <other_name>780</other_name>
    <other_name>Accutane</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>Claravis</other_name>
    <other_name>Sotret</other_name>
    <other_name>NSC#329481</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <arm_group_label>Non-intermediate risk enrolled on intermediate risk trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy &amp; continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.</description>
    <arm_group_label>Group 2 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 3 (chemotherapy, surgery)</arm_group_label>
    <arm_group_label>Group 4 (chemotherapy, surgery, antineoplastic therapy)</arm_group_label>
    <other_name>Granulocyte Colony-Stimulating Factor, r-metHuG-CSF, G-CSF, Neupogen, NSC #614629</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed neuroblastoma, ganglioneuroblastoma, or
             ganglioneuroma/maturing subtype

               -  Newly diagnosed disease

               -  Intermediate-risk disease

               -  Needle biopsies or involved bone marrow are not sufficient for INPC histologic
                  classification

          -  Meets 1 of the following criteria:

               -  Group 2

                    -  International Neuroblastoma Staging System (INSS) stage 2A/2B; &lt; 50%
                       resected or biopsy only; ≤ 12 years of age; MYCN-not amplified (NA); any
                       histology and ploidy; normal 1p and 11q

                    -  INSS stage 3; age &lt; 365 days; MYCN-NA; favorable histology (FH);
                       hyperdiploid (DI) &gt; 1; normal 1p and 11q

                    -  INSS stage 3; 365 days to 12 years of age; MYCN-NA; FH; normal 1p and 11q

                    -  INSS stage 4S; age &lt; 365 days; MYCN-NA; FH; DI &gt;1; normal 1p and 11q;
                       clinically symptomatic

               -  Group 3

                    -  INSS stage 2A/2B; &lt; 50% resected or biopsy only; ≤ 12 years of age; MYCN-NA;
                       any histology and ploidy; 1p loss of heterozygosity (LOH) and/or unb11q LOH
                       (or data missing for either)

                    -  INSS stage 3; age &lt; 365 days; MYCN-NA; FH; DI &gt; 1; 1p LOH and/or unb11q LOH
                       (or data missing for either)

                    -  INSS stage 3; age &lt; 365 days; MYCN-NA; DI = 1 and/or unfavorable histology
                       (UH); normal 1p and 11q

                    -  INSS stage 3; 365 days to 12 years of age; MYCN-NA; FH; 1p LOH and/or unb11q
                       LOH (or data missing for either)

                    -  INSS stage 4; age &lt; 365 days; MYCN-NA; FH; DI &gt; 1; normal 1p and 11q

                    -  INSS stage 4S; age &lt; 365 days; MYCN-NA; either UH and any ploidy or FH and
                       DI = 1; normal 1p and 11q

                    -  INSS stage 4S; age &lt; 365 days; MYCN-NA; FH; DI &gt; 1; 1p LOH and/or unb11q LOH
                       (or data missing for either); clinically symptomatic

               -  Group 4

                    -  INSS stage 3; age &lt; 365 days; MYCN-NA; DI = 1 and/or UH; 1p LOH and/or
                       unb11q LOH (or data missing for either)

                    -  INSS stage 3; age 365 to &lt; 547 days; MYCN-NA; UH; any ploidy; any 1p and 11q

                    -  INSS stage 4, age &lt; 365 days; MYCN-NA; DI = 1 and/or UH; any 1p and 11q

                    -  INSS stage 4; age &lt; 365 days; MYCN-NA; FH; DI &gt; 1; 1p LOH and/or unb11q LOH
                       (or data missing for either)

                    -  INSS stage 4; age 365 to &lt; 547 days; MYCN-NA; FH; DI &gt; 1; any 1p and 11q

                    -  INSS stage 4S; age &lt; 365 days; MYCN-NA; UH and any ploidy or FH and DI = 1;
                       1p LOH and/or unb11q LOH (or data missing for either)

                    -  INSS stage 4S; age &lt; 365 days; unknown or incomplete biologic features

                       8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin
                       hydrochloride, etoposide, filgrastim.

        Patients &lt; 12 months of age with stg 3, 4, or 4S disease who achieve a very good PR (VGPR)
        to chemo (with the exception of resolution of skin or liver metastases in stage 4S
        patients) proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve
        VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide
        and topotecan hydrochloride. Some patients may also undergo surgery.

          -  Must already be enrolled on protocol COG-ANBL00B1

               -  Simultaneous enrollment on COG-ANBL00B1 and this study allowed for clinical
                  situations in which emergent treatment may be indicated including, but not
                  limited to, the following criteria:

                    -  Epidural or intraspinal tumors with existing or impending neurologic
                       impairment

                    -  Periorbital or calvarial-based lesions with existing or impending cranial
                       nerve impairment

                    -  Anatomic or mechanical compromise of critical organ function by tumor (e.g.,
                       abdominal compartment syndrome, urinary obstruction)

                    -  Asymptomatic but, in the opinion of the treating physician, it is in the
                       patient's best interest to begin chemotherapy immediately due to impending
                       risk of neurologic impairment or organ dysfunction

          -  If patient receives study chemotherapy prior to undergoing diagnostic biopsy, the
             biopsy must be performed within 96 hours of beginning study therapy

               -  The only exception to this requirement is for patients with stage 4S disease who
                  are considered too ill to undergo a diagnostic procedure will be waived the
                  requirement for diagnostic tissue submission but will still need to be enrolled
                  on COG-ANBL00B1

                    -  For patients with stage 4S disease who are very ill and in whom an open
                       biopsy to obtain tissue for diagnosis and biologic studies is considered
                       medically contraindicated, every effort should be made to obtain some tumor
                       tissue by either fine-needle aspiration of a metastatic site of disease
                       and/or sampling of involved bone marrow, so that this tumor sample can be
                       submitted for MYCN determination

          -  Patients who require emergent therapy, either prior to the diagnostic biopsy or before
             biology features are available, can be enrolled simultaneously on COG-ANBL00B1 and
             COG-ANBL0531 to receive emergent protocol therapy

               -  In emergent circumstances, COG-ANBL0531 protocol therapy may be initiated prior
                  to enrollment on study as long as the patient has neuroblastoma by clinical
                  diagnosis, all other COG-ANBL0531 eligibility criteria are met, and the
                  COG-ANBL0531 Initial Therapy consent has been signed prior to starting protocol
                  therapy; in this circumstance ANBL0531 enrollment must occur within 4 working
                  days of starting protocol therapy

               -  Clinical situations in which emergent enrollment and treatment may be indicated
                  include, but are not limited to, the following circumstances:

                    -  Epidural or intraspinal tumors with existing or impending neurologic
                       impairment

                    -  Periorbital or calvarial-based lesions with existing or impending cranial
                       nerve impairment

                    -  Anatomic or mechanical compromise of critical organ function by tumor (e.g.,
                       abdominal compartment syndrome, urinary obstruction)

                    -  Evolving hepatomegaly in infants less than 2 months of age

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other prior chemotherapy or radiotherapy with the exception of dexamethasone

          -  No participation in another COG study with tumor therapeutic intent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clare Twist, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lucile Packard Children's Hospital at Stanford University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Lou Schmidt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonathan Jaques Children's Cancer Center at Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93638-8762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>95798</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Oakland</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian - St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20307-5001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center Cancer Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Cancer Care of Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist-South Miami Regional Cancer Program</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute at Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-1273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Cancer Institute at St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Cancer Center at St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Medical College of Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31403-3089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Tripler Army Medical Center</city>
        <state>Hawaii</state>
        <zip>96859-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712-6297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keyser Family Cancer Center at Advocate Hope Children's Hospital</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Cancer Care Center</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068-1174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cooper Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Office of Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71315-3198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare of Maine at Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program at Barbara Bush Children's Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074-9308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-5381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breslin Cancer Center at Ingham Regional Medical Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Cancer Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center at University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-2306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center Hospital</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208-3419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Cancer Center at Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals - Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308-1062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404-1815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center and Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-9786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134-1095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health South Carolina Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center at Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C. Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center School of Medicine - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3993</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113-1100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1971</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center - Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Medical Center for Children at Roanoke Community Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220-2555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Health Sciences Center - Charleston</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Regional Cancer Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's &amp; Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Children's Health and Rehabilitation Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Children's Health</name>
      <address>
        <city>Auckland</city>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>Santurce</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>December 1, 2015</results_first_submitted>
  <results_first_submitted_qc>May 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2017</results_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>localized resectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 2 (Chemotherapy, Surgery)</title>
          <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="P2">
          <title>Group 3 (Chemotherapy, Surgery)</title>
          <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="P3">
          <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
          <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="P4">
          <title>Non-intermediate Risk Enrolled on Intermediate Risk Trial</title>
          <description>The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
Surgery: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient/Parent Refusal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 2 (Chemotherapy, Surgery)</title>
          <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="B2">
          <title>Group 3 (Chemotherapy, Surgery)</title>
          <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="B3">
          <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
          <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S disease who achieve a very good PR (VGPR) to chemo (with the exception of resolution of skin or liver metastases in stage 4S patients) proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="B4">
          <title>Non-intermediate Risk Enrolled on Intermediate Risk Trial</title>
          <description>The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
Surgery: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="464"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.23" spread="1.47"/>
                    <measurement group_id="B2" value=".74" spread=".89"/>
                    <measurement group_id="B3" value=".60" spread=".36"/>
                    <measurement group_id="B4" value="1.51" spread="1.83"/>
                    <measurement group_id="B5" value="0.99" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="382"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) Rates</title>
        <description>OS time is calculated from date of enrollment until death, or until last contact if the patient is alive.</description>
        <time_frame>3 years</time_frame>
        <population>Eligible intermediate risk patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Rates</title>
          <description>OS time is calculated from date of enrollment until death, or until last contact if the patient is alive.</description>
          <population>Eligible intermediate risk patients.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.5" lower_limit="89.4" upper_limit="97.7"/>
                    <measurement group_id="O3" value="88.4" lower_limit="81.5" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Definitive Determination of the Prognostic Ability of 1p and 11q</title>
        <description>Addressed by a descriptive comparison of the EFS and OS rates for patients with 1p loss vs without 1p loss, and for those with unbalanced 11q vs normal 11q.</description>
        <time_frame>At baseline</time_frame>
        <population>Eligible intermediate risk patients with 1p and 11q data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Definitive Determination of the Prognostic Ability of 1p and 11q</title>
          <description>Addressed by a descriptive comparison of the EFS and OS rates for patients with 1p loss vs without 1p loss, and for those with unbalanced 11q vs normal 11q.</description>
          <population>Eligible intermediate risk patients with 1p and 11q data.</population>
          <units>percentage of 3 yr EFS/OS rate</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EFS Eligible &amp; evaluable patients without 1p loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="82.0" upper_limit="92.4"/>
                    <measurement group_id="O2" value="84.6" lower_limit="76.8" upper_limit="92.5"/>
                    <measurement group_id="O3" value="65.4" lower_limit="50.0" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS Eligible &amp; evaluable patients without 1p loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="92.8" lower_limit="87.2" upper_limit="98.4"/>
                    <measurement group_id="O3" value="83.7" lower_limit="71.6" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFS Eligible &amp; evaluable patients with 1p loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="94.7" lower_limit="84.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="81.8" lower_limit="65.2" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS Eligible &amp; evaluable patients with 1p loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="94.7" lower_limit="84.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="95.5" lower_limit="86.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFS Eligible &amp; evaluable patients with normal 11q</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="82.0" upper_limit="92.4"/>
                    <measurement group_id="O2" value="87.5" lower_limit="80.7" upper_limit="94.2"/>
                    <measurement group_id="O3" value="73.3" lower_limit="59.5" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS Eligible &amp; evaluable patients with normal 11q</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.7" lower_limit="88.7" upper_limit="98.7"/>
                    <measurement group_id="O3" value="87.7" lower_limit="77.4" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFS Eligible &amp; evaluable patients w/unbalanced 11q</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="75.0" lower_limit="45.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="65.5" lower_limit="42.7" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS Eligible &amp; evaluable patients w/unbalanced 11q</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="87.5" lower_limit="64.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="88.2" lower_limit="72.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between Reduce Intensity of Therapy for Patients With Stage 4 Neuroblastoma and Favorable Biological Features and Patients &lt; 1 Year of Age With Stage 4 Neuroblastoma Treated on COG-A3961</title>
        <description>Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients &lt; 1 yrs of age.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Eligible and evaluable patients with Stage 4 neuroblastoma, 12-18 months of age, and favorable biological features.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between Reduce Intensity of Therapy for Patients With Stage 4 Neuroblastoma and Favorable Biological Features and Patients &lt; 1 Year of Age With Stage 4 Neuroblastoma Treated on COG-A3961</title>
          <description>Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients &lt; 1 yrs of age.</description>
          <population>Eligible and evaluable patients with Stage 4 neuroblastoma, 12-18 months of age, and favorable biological features.</population>
          <units>percentage of 3 yr EFS rate</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="66.7" lower_limit="35.9" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The event-free survival distributions of patients between 12-18 months of age with Stage 4 neuroblastoma and favorable biological features on ANBL0531 and patients less than 12 months of age with Stage 4 neuroblastoma on A3961 were compared using the log-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.3212</p_value>
            <method>Log Rank</method>
            <param_type>Log Rank Test Statistic</param_type>
            <param_value>.9841</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison Between Reduce Intensity of Therapy for Patients With Unfavorable Histology Neuroblastoma and Patients Unfavorable Histology Neuroblastoma Treated on COG-A3961</title>
        <description>Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients &lt; 1 yrs of age</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Eligible and evaluable patients with Stage 3 neuroblastoma, 12-18 months of age, MYCN non-amplified, and unfavorable histology.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison Between Reduce Intensity of Therapy for Patients With Unfavorable Histology Neuroblastoma and Patients Unfavorable Histology Neuroblastoma Treated on COG-A3961</title>
          <description>Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients &lt; 1 yrs of age</description>
          <population>Eligible and evaluable patients with Stage 3 neuroblastoma, 12-18 months of age, MYCN non-amplified, and unfavorable histology.</population>
          <units>percentage of 3 yr EFS rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduced Surgical Morbidity for Patients With Stage 4S Neuroblastoma</title>
        <description>Descriptive analyses of the proportion of stage 4S infants that experience a surgical or post-operative event.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Eligible and evaluable patients with Stage 4S neuroblastoma that had a biopsy or resection.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduced Surgical Morbidity for Patients With Stage 4S Neuroblastoma</title>
          <description>Descriptive analyses of the proportion of stage 4S infants that experience a surgical or post-operative event.</description>
          <population>Eligible and evaluable patients with Stage 4S neuroblastoma that had a biopsy or resection.</population>
          <units>Proportion</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.06" upper_limit="0.41"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.03" upper_limit="0.31"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Outcome of Patients With Stage 4S Neuroblastoma Who Are Unable to Undergo Biopsy for Biology-based Risk Assignment</title>
        <description>Kaplan-Meier curves and lifetables of Event Free Survival (EFS) and Overall Survival (OS) rates will be generated to describe the outcome of the stage 4S infants unable to undergo biopsy.</description>
        <time_frame>From baseline to up to 10 years</time_frame>
        <population>Eligible and evaluable patients with Stage 4S neuroblastoma unable to undergo biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome of Patients With Stage 4S Neuroblastoma Who Are Unable to Undergo Biopsy for Biology-based Risk Assignment</title>
          <description>Kaplan-Meier curves and lifetables of Event Free Survival (EFS) and Overall Survival (OS) rates will be generated to describe the outcome of the stage 4S infants unable to undergo biopsy.</description>
          <population>Eligible and evaluable patients with Stage 4S neuroblastoma unable to undergo biopsy.</population>
          <units>percentage survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Event Free Survival (EFS)</title>
        <description>To test the predictive ability of the extent of surgical resection for EFS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>Eligible and evaluable intermediate risk patients with reported surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Event Free Survival (EFS)</title>
          <description>To test the predictive ability of the extent of surgical resection for EFS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.</description>
          <population>Eligible and evaluable intermediate risk patients with reported surgery</population>
          <units>percentage of 3 yr EFS survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EFS w/complete surgical resection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="90.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.4" lower_limit="78.7" upper_limit="98.1"/>
                    <measurement group_id="O3" value="78.6" lower_limit="63.4" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EFS w/o complete surgical resection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="74.6" upper_limit="89.8"/>
                    <measurement group_id="O2" value="85.1" lower_limit="77.7" upper_limit="92.4"/>
                    <measurement group_id="O3" value="69.2" lower_limit="56.3" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The event-free survival distributions of patients with complete surgical resection and patients without complete surgical resection were compared using the log-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.0253</p_value>
            <method>Log Rank</method>
            <param_type>Log-Rank Test Statistic</param_type>
            <param_value>5.0049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Overall Survival (OS) Rates</title>
        <description>To test the predictive ability of the extent of surgical resection for OS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>Eligible and evaluable intermediate risk patients with reported surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Overall Survival (OS) Rates</title>
          <description>To test the predictive ability of the extent of surgical resection for OS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.</description>
          <population>Eligible and evaluable intermediate risk patients with reported surgery.</population>
          <units>percentage of OS rate</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OS w/complete surgical resection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="95.4" lower_limit="89.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="96.4" lower_limit="89.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS w/o complete surgical resection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.5" lower_limit="88.4" upper_limit="98.6"/>
                    <measurement group_id="O3" value="86.5" lower_limit="77.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The overall survival distributions of patients with complete surgical resection and patients without complete surgical resection were compared using the log-rank test.</non_inferiority_desc>
            <p_value>.1022</p_value>
            <method>Log Rank</method>
            <param_type>Log Rank Test Statistic</param_type>
            <param_value>2.6709</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Surgical Complication Rate</title>
        <description>To test for the association of the extent of surgical resection (CR vs &lt;CR) with surgical complications rate (complications of any kind vs no complications at all), a chi-square test will be performed.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>Eligible and evaluable intermediate risk patients with reported surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Surgical Complication Rate</title>
          <description>To test for the association of the extent of surgical resection (CR vs &lt;CR) with surgical complications rate (complications of any kind vs no complications at all), a chi-square test will be performed.</description>
          <population>Eligible and evaluable intermediate risk patients with reported surgery</population>
          <units>Proportion with surgical complications</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR with complications</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".32" lower_limit=".22" upper_limit=".44"/>
                    <measurement group_id="O2" value=".19" lower_limit=".10" upper_limit=".33"/>
                    <measurement group_id="O3" value=".18" lower_limit=".08" upper_limit=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR with no complications</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".14" lower_limit=".09" upper_limit=".21"/>
                    <measurement group_id="O2" value=".13" lower_limit=".07" upper_limit=".21"/>
                    <measurement group_id="O3" value=".09" lower_limit=".04" upper_limit=".20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The association between extent of surgical resection with occurrence of complications was determined using the chi-square test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.0016</p_value>
            <method>Chi-squared</method>
            <param_type>Chi-Square Test Statistic</param_type>
            <param_value>9.9111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Second-event-free Survival (E2FS) of Intermediate Risk Patients</title>
        <description>Kaplan-Meier curves and life tables of E2FS and OS (from the time of first event) will be generated to describe the outcome for patients who have a first progressive, non-metastatic event during Observation and then receive protocol retrieval therapy.</description>
        <time_frame>From the time of the first progressive, non-metastatic event until the subsequent occurrence of relapse, progressive disease, secondary malignancy, or death</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time</title>
        <description>Kaplan-Meier curves and life tables of E2FS and OS (from the time of first event) will be generated to describe the outcome for patients who have a first progressive, non-metastatic event during Observation and then receive protocol retrieval therapy.</description>
        <time_frame>From the time of the first progressive, non-metastatic event</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biological Surrogate Markers</title>
        <description>Multivariable analyses will be performed to identify variables of prognostic interest.</description>
        <time_frame>At baseline and surgery</time_frame>
        <population>The data was not collected to assess this study aim.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Biological Surrogate Markers</title>
          <description>Multivariable analyses will be performed to identify variables of prognostic interest.</description>
          <population>The data was not collected to assess this study aim.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Neurologic Symptoms Overall and Type of Symptom</title>
        <description>Descriptive analysis will be used.</description>
        <time_frame>On treatment and post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Surgical Biopsy Technique With Adequacy of Tissue Acquisition for Biologic Studies, and With Complications Associated With the Biopsy Procedure</title>
        <description>A chi-square test will be performed.</description>
        <time_frame>During and after surgery</time_frame>
        <population>The data was not collected to assess this study aim.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 (Chemotherapy, Surgery)</title>
            <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 (Chemotherapy, Surgery)</title>
            <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
            <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Surgical Biopsy Technique With Adequacy of Tissue Acquisition for Biologic Studies, and With Complications Associated With the Biopsy Procedure</title>
          <description>A chi-square test will be performed.</description>
          <population>The data was not collected to assess this study aim.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prognostic Ability of the INRG Image-defined Risk Factor (IDRF) System</title>
        <description>A Kaplan – Meier curves of presence vs absence of one or more IDRFs will be generated, and a log rank test performed to compare them, for EFS and OS. The IDRF data will be used to determine the International Neuroblastoma Risk Group Stage (INRGSS) and Kaplan-Meier curves by INRGSS will be generated. To compare the institutional assessment of IDRFs (presence vs absence) with the central review assessment of IDRFs, a chi-square test will be performed. ROC curves will be generated, and the sensitivity and specificity of the institutional assessment will be calculated</description>
        <time_frame>At baseline, during and after completion of study treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>SAE field contains NCI CTCAEs submitted via expedited reporting (NCI AdEERs / CAeRs). The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 2 (Chemotherapy, Surgery)</title>
          <description>2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="E2">
          <title>Group 3 (Chemotherapy, Surgery)</title>
          <description>4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="E3">
          <title>Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)</title>
          <description>8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients &lt; 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.</description>
        </group>
        <group group_id="E4">
          <title>Non-intermediate Risk Enrolled on Intermediate Risk Trial</title>
          <description>The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
Surgery: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>46300-Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>24600-Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>55700-Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>40600-Hepatobiliary disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>44800-Infections and infestations - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>73700-Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>80700-Tracheal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>71000-Renal and urinary disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>19200-Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>71500-Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="94" subjects_affected="60" subjects_at_risk="175"/>
                <counts group_id="E2" events="102" subjects_affected="64" subjects_at_risk="140"/>
                <counts group_id="E3" events="105" subjects_affected="45" subjects_at_risk="89"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>17200-Blood and lymphatic system disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>25800-Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>33300-Febrile neutropenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="175"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="140"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>20000-Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>51700-Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>87100-Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>55000-Middle ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>29200-Endocrine disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>31900-Eye disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>10100-Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>10300-Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>14900-Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>25700-Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>27600-Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>36700-Gastrointestinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>37600-Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>44600-Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>46300-Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>49400-Jejunal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>53900-Malabsorption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>57600-Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>75700-Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>75900-Small intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>81900-Typhlitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>87900-Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>28200-Edema face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>28300-Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>28400-Edema trunk</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>33900-Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>34600-Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>35000-Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43700-Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>48700-Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>58600-Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>60600-Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>35400-Gallbladder obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>40000-Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>66600-Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>13100-Anaphylaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>10200-Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>16600-Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>16800-Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>18800-Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>20500-Catheter related infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>29500-Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>32000-Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>38300-Gum infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>44800-Infections and infestations - Other specify</sub_title>
                <counts group_id="E1" events="50" subjects_affected="32" subjects_at_risk="175"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="140"/>
                <counts group_id="E3" events="60" subjects_affected="34" subjects_at_risk="89"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>50300-Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>53100-Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>60100-Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>69800-Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>72600-Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>75200-Skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>80900-Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>82300-Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>83100-Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>88900-Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>14500-Arterial injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>86400-Vascular access complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>11800-Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>34000-Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>37500-GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>45800-INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>52600-Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>53700-Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="140"/>
                <counts group_id="E3" events="28" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="173" subjects_affected="99" subjects_at_risk="175"/>
                <counts group_id="E2" events="178" subjects_affected="86" subjects_at_risk="140"/>
                <counts group_id="E3" events="156" subjects_affected="55" subjects_at_risk="89"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="79" subjects_affected="57" subjects_at_risk="175"/>
                <counts group_id="E2" events="85" subjects_affected="56" subjects_at_risk="140"/>
                <counts group_id="E3" events="75" subjects_affected="40" subjects_at_risk="89"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>88300-Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>88500-White blood cell decreased</sub_title>
                <counts group_id="E1" events="72" subjects_affected="47" subjects_at_risk="175"/>
                <counts group_id="E2" events="89" subjects_affected="60" subjects_at_risk="140"/>
                <counts group_id="E3" events="72" subjects_affected="36" subjects_at_risk="89"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>11900-Alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>13500-Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>24700-Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>41300-Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>41400-Hyperglycemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>41600-Hyperkalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>41700-Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>41800-Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>42500-Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>42700-Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>42900-Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="140"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43500-Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>81700-Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>16200-Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>38700-Head soft tissue necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>55900-Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>58000-Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>81800-Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>22000-Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>25300-Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>27700-Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>29000-Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>58100-Nervous system disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>63900-Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>64100-Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>70900-Recurrent laryngeal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>73600-Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>68300-Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>83000-Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>11300-Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>14100-Apnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>15100-Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>15400-Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>19200-Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>19300-Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>21900-Chylothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>27800-Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>65900-Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>66300-Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>66400-Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>60800-Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>74700-Skin and subcutaneous tissue disorders - Other specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>84100-Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>19800-Capillary leak syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>39100-Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>42100-Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="15" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>53300-Lymph leakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>79600-Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior Sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

